博瑞医药跌2.01%，成交额6.05亿元，主力资金净流出6693.04万元

Company Overview - 博瑞医药 (Borui Pharmaceutical) is located in Suzhou Industrial Park, Jiangsu Province, and was established on October 26, 2001. The company went public on November 8, 2019. Its main business involves the research and production of high-end generic drugs and original new drugs [1]. Stock Performance - As of September 3, the stock price of 博瑞医药 was 89.41 CNY per share, with a market capitalization of 37.8 billion CNY. The stock has increased by 197% year-to-date but has seen a decline of 14.85% over the last five trading days and 21.57% over the last 20 days [1]. - The trading volume on September 3 was 605 million CNY, with a turnover rate of 1.57% [1]. Financial Performance - For the first half of 2025, 博瑞医药 reported a revenue of 537 million CNY, a year-on-year decrease of 18.28%. The net profit attributable to shareholders was 17.17 million CNY, down 83.85% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 246 million CNY, with 129 million CNY distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders was 9,568, a decrease of 10.11% from the previous period. The average number of circulating shares per person increased by 11.32% to 44,185 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 3.25 million shares, a decrease of 1.06 million shares from the previous period. 新进股东 (Innovation Drug) is the tenth largest shareholder with 2.81 million shares [3].